232 related articles for article (PubMed ID: 24612787)
21. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
22. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer.
Okuno K; Sugiura F; Inoue K; Sukegawa Y
Anticancer Res; 2014 Jun; 34(6):3045-52. PubMed ID: 24922671
[TBL] [Abstract][Full Text] [Related]
23. Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele.
Sakamoto S; Matsueda S; Takamori S; Toh U; Noguchi M; Yutani S; Yamada A; Shichijo S; Yamada T; Suekane S; Kawano K; Sasada T; Hattori N; Kohno N; Itoh K
Cancer Sci; 2015 Oct; 106(10):1257-63. PubMed ID: 26212219
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
[TBL] [Abstract][Full Text] [Related]
25. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.
Sundar R; Rha SY; Yamaue H; Katsuda M; Kono K; Kim HS; Kim C; Mimura K; Kua LF; Yong WP
BMC Cancer; 2018 Mar; 18(1):332. PubMed ID: 29587677
[TBL] [Abstract][Full Text] [Related]
26. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.
Kawamura J; Sugiura F; Sukegawa Y; Yoshioka Y; Hida JI; Hazama S; Okuno K
Cancer Sci; 2018 May; 109(5):1545-1551. PubMed ID: 29473265
[TBL] [Abstract][Full Text] [Related]
28. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
[TBL] [Abstract][Full Text] [Related]
29. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
30. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.
Speetjens FM; Kuppen PJ; Welters MJ; Essahsah F; Voet van den Brink AM; Lantrua MG; Valentijn AR; Oostendorp J; Fathers LM; Nijman HW; Drijfhout JW; van de Velde CJ; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Feb; 15(3):1086-95. PubMed ID: 19188184
[TBL] [Abstract][Full Text] [Related]
31. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.
Kono K; Iinuma H; Akutsu Y; Tanaka H; Hayashi N; Uchikado Y; Noguchi T; Fujii H; Okinaka K; Fukushima R; Matsubara H; Ohira M; Baba H; Natsugoe S; Kitano S; Takeda K; Yoshida K; Tsunoda T; Nakamura Y
J Transl Med; 2012 Jul; 10():141. PubMed ID: 22776426
[TBL] [Abstract][Full Text] [Related]
32. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients.
Sato Y; Maeda Y; Shomura H; Sasatomi T; Takahashi M; Une Y; Kondo M; Shinohara T; Hida N; Katagiri K; Sato K; Sato M; Yamada A; Yamana H; Harada M; Itoh K; Todo S
Br J Cancer; 2004 Apr; 90(7):1334-42. PubMed ID: 15054451
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer.
Kibe S; Yutani S; Motoyama S; Nomura T; Tanaka N; Kawahara A; Yamaguchi T; Matsueda S; Komatsu N; Miura M; Hinai Y; Hattori S; Yamada A; Kage M; Itoh K; Akagi Y; Sasada T
Cancer Immunol Res; 2014 Dec; 2(12):1154-62. PubMed ID: 25351849
[TBL] [Abstract][Full Text] [Related]
35. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
Hasegawa K; Ikeda Y; Kunugi Y; Kurosaki A; Imai Y; Kohyama S; Nagao S; Kozawa E; Yoshida K; Tsunoda T; Nakamura Y; Fujiwara K
J Immunother; 2018 May; 41(4):201-207. PubMed ID: 29432282
[TBL] [Abstract][Full Text] [Related]
36. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
Obara W; Eto M; Mimata H; Kohri K; Mitsuhata N; Miura I; Shuin T; Miki T; Koie T; Fujimoto H; Minami K; Enomoto Y; Nasu T; Yoshida T; Fuse H; Hara I; Kawaguchi K; Arimura A; Fujioka T
Ann Oncol; 2017 Apr; 28(4):798-803. PubMed ID: 27998971
[TBL] [Abstract][Full Text] [Related]
37. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
Rahma OE; Hamilton JM; Wojtowicz M; Dakheel O; Bernstein S; Liewehr DJ; Steinberg SM; Khleif SN
J Transl Med; 2014 Feb; 12():55. PubMed ID: 24565030
[TBL] [Abstract][Full Text] [Related]
38. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides.
Kavanagh B; Ko A; Venook A; Margolin K; Zeh H; Lotze M; Schillinger B; Liu W; Lu Y; Mitsky P; Schilling M; Bercovici N; Loudovaris M; Guillermo R; Lee SM; Bender J; Mills B; Fong L
J Immunother; 2007 Oct; 30(7):762-72. PubMed ID: 17893568
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
[TBL] [Abstract][Full Text] [Related]
40. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
Hazama S; Takenouchi H; Tsunedomi R; Iida M; Suzuki N; Iizuka N; Inoue Y; Sakamoto K; Nakao M; Shindo Y; Kanekiyo S; Tokumitsu Y; Yoshimura K; Maeda N; Maeda K; Maeda Y; Matsui H; Yoshino S; Nakamura Y; Fujita Y; Hamamoto Y; Okamoto M; Fujita T; Kawakami Y; Oka M
Anticancer Res; 2014 Aug; 34(8):4201-5. PubMed ID: 25075047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
